Improved Prediction of CYP2D6 Catalyzed Drug Metabolism by Taking Variant Substrate Specificities and Novel Polymorphic Haplotypes into Account
Clinical Pharmacology & Therapeutics · 2025-07 · 118 (1) · 218-231
DOI: 10.1002/cpt.3680 ↗At a glance
Journal article in Clinical Pharmacology & Therapeutics, published online on 2025-04-22. Written by Inger Johansson and 11 co-authors. Institution: Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. Major MEDLINE topics: Cytochrome P-450 CYP2D6, Tamoxifen, Risperidone. Cited 11 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
The polymorphic CYP2D6 enzyme plays a pivotal role in the metabolism of approximately 25% of clinically prescribed drugs. However, the impact of specific genetic variants on the interindividual variability in CYP2D6‐mediated drug metabolism remains insufficiently quantified. This translational study sought to address this gap by analyzing the genotypes and phenotypes of patients in two large clinical cohorts, focusing on the metabolism of the CYP2D6 substrates risperidone and desmethyltamoxifen. The analysis incorporated novel polymorphic haplotypes and substrate‐specific differences among the CYP2D6.1, CYP2D6.2, and CYP2D6.35 enzyme variants. The study revealed that CYP2D6.2 and CYP2D6.35 exhibit reduced metabolic capacity for these substrates, both in vivo and in an in vitro expression model. This was evidenced by decreased catalytic turnover (Kcat), decreased substrate affinity, and altered substrate docking. Furthermore, novel polymorphic haplotypes on the CYP2D6*1, CYP2D6*2, and CYP2D6*35 backgrounds were identified, each associated with a 30–40% increase in CYP2D6 activity. Incorporating these findings into prediction equations significantly improved the genetic prediction accuracy ( R 2 ) for CYP2D6‐mediated metabolism of desmethyltamoxifen from 59% to 71% and risperidone, also metabolized by CYP3A4, from 42% to 46%. These results highlight the importance of accounting for drug‐specific interactions with enzyme variants and integrating distinct polymorphic haplotypes into CYP pharmacogenomic models and guidelines for better translation into clinical practice.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
- Center for Molecular Medicine, Karolinska Institutet and University Hospital, Stockholm, Sweden.
- Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Netherlands.
- Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.
- Department of Pharmacy, University of Oslo, Oslo, Norway.
- Department of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
ORCID profiles: Inger Johansson, Emmanouella M Xanthopoulou, Yitian Zhou, Anabel Sanchez-Spitman, Maaike van der Lee, Birgit M Wollmann, Elisabet Størset, Jesse J Swen, Henk-Jan Guchelaar, Espen Molden, Marin M Jukic, Magnus Ingelman-Sundberg
Cite
APA
Johansson, I., Xanthopoulou, E. M., Zhou, Y., Sanchez-Spitman, A., van der Lee, M., Wollmann, B. M., Størset, E., Swen, J. J., Guchelaar, H. J., Molden, E., Jukic, M. M., & Ingelman-Sundberg, M. (2025). Improved Prediction of CYP2D6 Catalyzed Drug Metabolism by Taking Variant Substrate Specificities and Novel Polymorphic Haplotypes into Account. Clinical Pharmacology & Therapeutics, 118(1), 218-231. https://doi.org/10.1002/cpt.3680
Vancouver
Johansson I, Xanthopoulou EM, Zhou Y, Sanchez-Spitman A, van der Lee M, Wollmann BM, et al. Improved Prediction of CYP2D6 Catalyzed Drug Metabolism by Taking Variant Substrate Specificities and Novel Polymorphic Haplotypes into Account. Clinical Pharmacology & Therapeutics. 2025;118(1):218-231. doi:10.1002/cpt.3680
BibTeX
@article{Johansson2025,
author = {Johansson, Inger and Xanthopoulou, Emmanouella M and Zhou, Yitian and Sanchez-Spitman, Anabel and van der Lee, Maaike and Wollmann, Birgit M and Størset, Elisabet and Swen, Jesse J and Guchelaar, Henk-Jan and Molden, Espen and Jukic, Marin M and Ingelman-Sundberg, Magnus},
title = {Improved Prediction of CYP2D6 Catalyzed Drug Metabolism by Taking Variant Substrate Specificities and Novel Polymorphic Haplotypes into Account},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
volume = {118},
number = {1},
pages = {218--231},
doi = {10.1002/cpt.3680}
}
EUVIMED